Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-Fresenius S added to standard graft-versus-host disease prophylaxis in matched unrelated donor allogeneic stem cell transplantation
2004-000232-91Phase 3Completed
- Sponsor
- Fresenius
- Start
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by Fresenius. Primary endpoint: Early treatment failure. Started Sep 2004; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2004-000232-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000232-91.